Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vir Biotechnology : GlaxoSmithKline Secure Deal With EU for Supply of Experimental COVID-19 Treatment

07/28/2021 | 11:13am EDT


© MT Newswires 2021
All news about VIR BIOTECHNOLOGY, INC.
09/08VIR BIOTECHNOLOGY : to Participate in the Morgan Stanley 19th Annual Global Heal..
AQ
09/07Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global In..
GL
08/27U.S. resumes supply of Lilly's COVID-19 antibody combo to some states
RE
08/23VIR BIOTECHNOLOGY : Secures Provisional Marketing Approval for COVID-19 Treatmen..
MT
08/23VIR BIOTECHNOLOGY : Announces First Marketing Authorization for its First Commer..
AQ
08/23Vir Biotechnology, Inc. Announces First Marketing Authorization for Its First..
CI
08/20AstraZeneca's antibody therapy prevents COVID-19, study shows
RE
08/06SECTOR UPDATE : Health Care Pulls Back Ahead of Friday Opener
MT
08/06VIR BIOTECHNOLOGY : Swings to Surprise Profit in Q2 as Revenue Climbs
MT
08/05VIR BIOTECHNOLOGY : Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q2 Revenue $1..
MT
More news
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 399 M - -
Net income 2021 -206 M - -
Net cash 2021 1 004 M - -
P/E ratio 2021 -33,4x
Yield 2021 -
Capitalization 6 871 M 6 871 M -
EV / Sales 2021 14,7x
EV / Sales 2022 12,7x
Nbr of Employees 367
Free-Float 86,9%
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 52,61 $
Average target price 69,86 $
Spread / Average Target 32,8%
EPS Revisions
Managers and Directors
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.96.45%6 871
MODERNA, INC.321.80%175 368
LONZA GROUP AG34.92%61 973
IQVIA HOLDINGS INC.43.91%49 541
CELLTRION, INC.-25.63%31 848
SEAGEN INC.-12.32%27 670